CHUGAI SEIYAKU KABUSHIKI KAISHA (CHUGAIPHARMACEUTICAL CO., LTD.)

ACT-IG

Pharmaceutical preparations for human use, namely, pharmaceutical antibodies and their fragments and derivatives, cells and genes that produces antibodies, and fragments of antibodies and derivatives of antibodies, all for preventing or treating infectious and parasitic diseases, cancer, blood and blood-forming organs diseases and disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, pregnancy, childbirth and the puerperium, and congenital malformations, deformations and chromosomal abnormalities, for medical and pharmaceutical use;Granting of licenses to others for the use of industrial property rights and copyright;Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals;

ANTEVAS

pharmaceutical preparations, namely anti-neurodegenerative drugs, drugs for treating cerebrovascular and peripheral vascular diseases, organ transplant protectants, anti-ulcer and anti-cancer drugs;The Japanese characters in the mark are transliterated into ANTEVAS, which is a coined word and has no meaning.;

ANTEVAS

PHARMACEUTICAL PREPARATIONS, NAMELY ANTI-NEURODEGENERATIVE DRUGS, DRUGS FOR TREATING CEREBROVASCULAR AND PERIPHERAL VASCULAR DISEASES, ORGAN TRANSPLANT PROTECTANTS, ANTI-ULCER AND ANTI-CANCER DRUGS;

ART-FC

Pharmaceutical preparations for human use to control binding activity to Fc receptors through asymmetric mutations, namely, pharmaceutical antibodies or its fragments or its derivatives, cells and genes that produce antibodies, fragments of antibodies or derivatives of antibodies for medical and pharmaceutical use;Granting of licenses to others for the use of industrial property rights and copyrights;Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals;

ART-IG

Pharmaceutical preparations, all for preventing or treating infectious and parasitic diseases, cancer, blood and blood-forming organs diseases and disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, pregnancy, childbirth and the puerperium, and congenital malformations, deformations and chromosomal abnormalities in humans, namely, pharmaceutical antibodies or its fragments or its derivatives, cells and genes that produces antibodies, fragments of antibodies or derivatives of antibodies for medical and pharmaceutical use;Granting of licenses to others for the use of industrial property rights and copyright;Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals;

CAYTISU

Natural biomaterials for augmentation of bone, cartilage and tissue for medical purposes; Biological materials, namely, cellular tissue, connective tissue, living tissue, and living cells for medical implantation; Pharmaceutical preparations for the treatment of cartilage defect and osteoarthritis;Surgical instruments and apparatus; Medical apparatus and instruments for use in orthopedic surgery; Implants consisting primarily of artificial materials and also including biological materials; Medical, surgical and orthopedic implants made of artificial materials;

CHUGAI

pharmaceutical preparations; namely, anti ulcerants, anti anginal drugs, anti cerebro-vasospasm and edema drugs, anti psoriasis, and chemotherapeutics;

CIVUPLIM

Pharmaceutical preparations for the treatment of hematological diseases and disorders;

CIVWING

Pharmaceutical preparations for the treatment of hematological diseases and disorders;

COCOWEY

Pharmaceutical preparations for the treatment of diabetes mellitus;

DYNREMY

Pharmaceutical preparations for the treatment of neuromyelitis optica spectrum disorder;

ENSPRYNG

Providing educational classes, seminars, workshops, symposiums and conferences and training services in the medical field;The mark consists of the stylized wording ENSPRYNG with a stylized curved spring design above.;Color is not claimed as a feature of the mark.;Providing medical information on pharmaceuticals and other medical information;

FAST-IG

Pharmaceutical preparations for human use, namely, pharmaceutical antibodies or its fragments or its derivatives; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical use;

FAST-IG

Granting of licenses to others in connection with pharmaceutical antibodies or its fragments or its derivatives, or cells for the use of industrial property rights and copyright;Pharmaceutical research services and providing information about medical and scientific research in the field of pharmaceuticals;

FIDCROY

Pharmaceutical preparations for the treatment of hematological diseases and disorders;

FRICUTRI

Natural biomaterials for augmentation of bone, cartilage and tissue for medical purposes; Biological materials, namely, cellular tissue, connective tissue, living tissue, and living cells for medical implantation; Pharmaceutical preparations for the treatment of cartilage defect and osteoarthritis;Surgical instruments and apparatus; Medical apparatus and instruments for use in orthopedic surgery; Implants consisting primarily of artificial materials and also including biological materials; Medical, surgical and orthopedic implants made of artificial materials;

GK

The mark consists of the stylized Greek letter Delta and the stylized Latin letters GK.;Pharmaceutical preparations for human use to minimize heterogeneity caused by endogenous enzymes in the course of cell culture for preventing or treating infectious and parasitic diseases, cancer, blood and blood-forming organs diseases and disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, pregnancy, childbirth and the puerperium, certain conditions originating in the perinatal period, congenital malformations, deformations and chromosomal abnormalities, namely, pharmaceutical antibodies or its fragments or its derivatives; cells and genes that produce antibodies, fragments of antibodies or derivatives of antibodies for medical use;Color is not claimed as a feature of the mark.;The transliteration of the non-Latin characters in the mark is: delta.;Granting of licenses to others for the use of industrial property rights and copyright;Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals;